  This paper presents a mathematical model for tumour-immune response
interactions in the perspective of immunotherapy by immune checkpoint
inhibitors ICIs. The model is of the nonlocal integro-differential
Lotka-Volterra type, in which heterogeneity of the cell populations is taken
into account by structuring variables that are continuous internal traits (aka
phenotypes) present in each individual cell. These represent a lumped
``aggressiveness'', i.e., for tumour cells, malignancy understood as the
ability to thrive in a viable state under attack by immune cells or drugs -
which we propose to identify as a potential of de-differentiation -, and for
immune cells, ability to kill tumour cells, in other words anti-tumour
efficacy. We analyse the asymptotic behaviour of the model in the absence of
treatment. By means of two theorems, we characterise the limits of the
integro-differential system under an a priori convergence hypothesis. We
illustrate our results with a few numerical simulations, which show that our
model reproduces the three Es of immunoediting: elimination, equilibrium, and
escape. Finally, we exemplify the possible impact of ICIs on these three Es.
